Silence Therapeutics Q2 EPS (11.10) Pence Down From (9.60) Pence YoY, Sales £598.00K Down From £9.10M YoY, Cash, Cash Equivalents And U.S. Treasury Bills of £149.6M(~$189.2M)
Portfolio Pulse from Benzinga Newsdesk
Silence Therapeutics reported a Q2 EPS of (11.10) pence, down from (9.60) pence year-over-year. Sales decreased significantly to £598.00K from £9.10M YoY. The company holds cash, cash equivalents, and U.S. Treasury bills totaling £149.6M (~$189.2M).
August 15, 2024 | 11:42 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Silence Therapeutics reported a significant decline in Q2 EPS and sales year-over-year, indicating potential financial struggles. However, the company maintains a strong cash position.
The significant decline in EPS and sales suggests financial difficulties, which is likely to negatively impact the stock price in the short term. However, the strong cash position may provide some buffer.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100